Human mitochondrial genetics

Mitochondrial DNA Analysis Is Added to OmniTier’s CompStor® Family of Genomics Secondary and Tertiary Analysis Appliances

Retrieved on: 
Monday, March 1, 2021
Data management, Biotechnology, Technology, Health, General Health, Other Technology, Medical devices, Research, Software, Science, Hardware, Branches of biology, Genetics, Biology, DNA, Genomics, Mitochondrial genetics, Genetic mapping, Cellular respiration, Mitochondrion, Mitochondrial DNA, Human mitochondrial genetics, Genome, Mitochondrial DNA analysis, CompStor Novos®, CompStor Insight™, OmniTier

OmniTier announced today that its CompStor family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.

Key Points: 
  • OmniTier announced today that its CompStor family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.
  • Variant calling on the mitochondrial genome must overcome additional challenges that are not present in standard nuclear genome analysis.
  • Because mitochondrial DNA is circular, standard linear analysis produces errors at the ostensible extremities of the mitochondrial sequence.
  • In addition, the number of types of mitochondrial DNA that may be present in a single sample is not simply bounded.

Mitochondrial Disease Therapies Market, 2019-2030

Retrieved on: 
Wednesday, October 16, 2019
Branches of biology, Mitochondrial genetics, Biology, Molecular biology, Mitochondrial diseases, Mitochondrial disease, Mitochondrial DNA, Mitochondrion, Human mitochondrial genetics, MERRF syndrome, Taosheng Huang

DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases.
  • The chapter lays emphasis on genetic diseases caused due to mutations in the mitochondrial DNA and clinical conditions that are associated with mitochondrial dysfunction.
  • Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of mitochondrial disease therapies till the year 2030.

Leading mitochondrial DNA researcher discusses causes of common complex diseases at Feinstein Institute Marsh Lecture

Retrieved on: 
Thursday, June 21, 2018
Biology, Mitochondrial genetics, Cellular respiration, Mitochondria, Mitochondrion, Mitochondrial DNA, Human mitochondrial genetics, Leonard Marsh

Dr. Wallace discussed his research to determine the mitochondrial causes of common "complex" diseases.

Key Points: 
  • Dr. Wallace discussed his research to determine the mitochondrial causes of common "complex" diseases.
  • The mitochondria also contain their own DNA, the mitochondrial DNA (mtDNA), which encodes the wiring diagram for the cell's power plants.
  • The Feinstein Institute's Marsh Lecture was established as a forum for renowned scientists to share their expertise with Feinstein Institute investigators.
  • Made possible by an endowment from the late Leonard Marsh and his family, the Marsh Lecture honors the memory of Leonard Marsh, co-founder of Snapple Beverage Corporation and a major supporter of the Feinstein Institute.